key: cord-0946357-ne816kr4 authors: Cao, Junyuan; Liu, Yang; Zhou, Minmin; Dong, Siqi; Jia, Xiaoying; Lan, Xiaohao; Zhang, Yueli; Guo, Jiao; Xiao, Gengfu; Wang, Wei title: Screening of Botanical Drugs against SARS-CoV-2 Entry date: 2021-06-04 journal: bioRxiv DOI: 10.1101/2021.06.03.447021 sha: 0f8501e8bdf4b2550dbb95839214d0297c8a496b doc_id: 946357 cord_uid: ne816kr4 An escalating pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacting global health. Specific treatment options for diseases caused by SARS-CoV-2 are largely lacking. Herein, we used a pseudotype virus (pv) bearing the SARS-CoV-2 S glycoprotein to screen a botanical drug library to identify an agent against SARS-CoV-2 entry. All the four hits, including angeloylgomisin O, schisandrin B, procyanidin, and oleanonic acid, were identified for effective inhibition of SARS-CoV-2 S pv entry in the micromolar range. A mechanistic study revealed that these four agents inhibit SARS-CoV-2 S pv entry by blocking S-mediated membrane fusion. Furthermore, angeloylgomisin O, schisandrin B, and oleanonic acid inhibited authentic SARS-CoV-2 with a high selective index (SI). We also showed that all the four hits could also inhibit the entry of pv of Middle East respiratory syndrome coronavirus (MERS-CoV) and newly emerged SARS-CoV-2 variants (D614G, K417N/E484K/N501Y/D614G). In drug combination studies performed in cellular antiviral assays, angeloylgomisin O and schisandrin B displayed synergistic effects in combination with remdesivir. These results indicated that angeloylgomisin O, schisandrin B, procyanidin, and oleanonic acid can inhibit SARS-CoV-2 and that they are potential therapeutic agents for COVID-19. angeloylgomisin O, schisandrin B, and oleanonic acid inhibited authentic SARS-CoV-2 with 24 a high selective index (SI) . We also showed that all the four hits could also inhibit the entry of 25 pv of Middle East respiratory syndrome coronavirus (MERS-CoV) and newly emerged 26 SARS-CoV-2 variants (D614G, K417N/E484K/N501Y/D614G). In drug combination studies 27 performed in cellular antiviral assays, angeloylgomisin O and schisandrin B displayed 28 synergistic effects in combination with remdesivir. These results indicated that 29 angeloylgomisin O, schisandrin B, procyanidin, and oleanonic acid can inhibit SARS-CoV-2 30 and that they are potential therapeutic agents for COVID-19. 31 COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), 34 poses a severe threat to global public health as well as economic and social stability, requiring 35 rapid development of treatment and preventive measures (1) . 36 Coronavirus is an enveloped virus with four structural proteins: spike (S), membrane (M), 37 envelope (E), and nucleocapsid (N) proteins. SARS-CoV-2 shares a high degree of sequence 38 identity with SARS-CoV that emerged previously and exploits the same human cell receptor, 39 angiotensin-converting enzyme 2 (ACE2), for infection (2, 3). After the receptor binding 40 domain (RBD) in the S1 subunit of the S protein on the virion binds to the ACE2 receptor on 41 the target cell, the heptapeptide repeat 1 (HR1) and 2 (HR2) domains in the S2 subunit of the 42 S protein interact with each other to form a six-helix bundle (6-HB) fusion nucleus. This 43 interaction brings the virus membrane and cell membrane close together for fusion and 44 infection (4, 5) . 45 concentration (400 μM). Schisandrin B inhibited SARS-CoV-2 S pv (ct19) by 90% at 100 μM, 113 whereas the cell viability was approximately 80% at 400 μM (Fig. 3B ). Procyanidin at 50 μM 114 and 100 μM inhibited SARS-CoV-2 S pv (ct19) by approximately 80% and 95%, respectively. 115 The cell viability was approximately 80% at 400 μM (Fig. 3C ). Oleanolic acid (50 μM) 116 inhibited SARS-CoV-2 S pv (ct19) by approximately 70% (Fig. 3D ). While it is relatively 117 toxic to Caco-2 cells with a 50% cytotoxic concentration (CC 50 ) of 53.88 μM. To validate the 118 antiviral effects, four hits were purchased from other commercial sources and tested. The 119 antiviral effects were similar to those observed in our primary screening. 120 121 To explore the antiviral mechanical properties of the four hits, the effects of the four hits on 123 SARS-CoV-2 S-mediated membrane fusion were examined. Recent research has identified 124 that SARS-CoV-2 induces syncytia formation in the lungs of patients with . It 125 was reported that cells infected with SARS-CoV-2 exhibited a typical syncytium phenomenon 126 (5). In this assay, fusion activity was conducted by co-transfecting SARS-CoV-2 S (ct19) and 127 green fluorescent protein (GFP) into Vero E6 cells. After 24 h, the S protein of SARS-CoV-2 128 induced cell-cell fusion, resulting in the formation of syncytia (Fig. 4A ). 25-hydrocholesterol 129 (25HC) was used as the positive control (23, 24). As shown in Fig. 4A , 25 μM of 25HC 130 blocked syncytia formation. Likewise, all the four hits induced a dose-dependent reduction in 131 syncytium size (Fig. 4B ). Angeloylgomisin O blocked syncytia formation at a concentration 132 of 6.25 μM, while procyanidin, oleanonic acid, and schisandrin B required higher 133 concentrations (12.5 μM to 25 μM) to achieve the inhibition (Fig. 4B) . These results 134 suggested that angeloylgomisin O, schisandrin B, procyanidin, and oleanonic acid could 135 inhibit SARS-CoV-2 entry by inhibiting membrane fusion. 136 137 To evaluate the inhibition of four hits on authentic SARS-CoV-2, an immunofluorescence 139 assay (IFA) was carried out using SARS-CoV-2 NP antibody. As shown in respectively. Indicating that their therapeutic potential against MERS-CoV. MERS-CoV 158 employed the different receptor, dipeptidyl peptidase-4 (DPP4), from the SARS-CoV-2. It 159 could be ruled out that four hits only interfere with ACE2 to block pseudovirus entry (25, 26) . In this study, we screened a botanical drug library containing 1,037 compounds and identified 200 four hits, including angeloylgomisin O, procyanidin, schisandrin B, and oleanonic acid, which 201 blocked the entry of SARS-CoV-2 S (ct19) pv infection by inhibiting viral membrane fusion. 202 Furthermore, the four hits inhibited the SARS-CoV-2 authentic virus at the micromolar level. 203 The top two compounds angeloylgomisin O and schisandrin B inhibited authentic 204 SARS-CoV-2 at a highly selective index (SI). All the four hits inhibited MERS-CoV S pv, 205 SARS-CoV-2 S D614G pv, and SARS-CoV-2 S pv K417N/E484K/N501Y/D614G infection. 206 Remdesivir-angeloylgomisin O drug combination showed stronger antiviral activities against 207 SARS-CoV-2 than remdesivir monotherapy. 208 The top two hits, angeloylgomisin O and schisandrin B, were derived from Schisandra 209 chinensis. Fruit from this plant and its extracts were used in traditional medicine in East Asia 210 to treat liver disorders such as hepatitis. They also possess a broad spectrum of biological and 211 pharmacological uses, including antiviral, anti-inflammatory, and antioxidative properties, 212 without toxicity (32). Schisandrin B has been shown to inhibit cytochrome P450 3A (CYP3A) 213 activity in rat liver and thus affects the metabolism of many drugs (33, 34). Furthermore, 214 upon rat oral administration of Schisandra chinensis extract, schisandrin B has been reported 215 to accumulate to a maximum plasma concentration (C max ) of 4.54 μM (35). This value was 216 similar to the IC 50 value for schisandrin B in the present study, suggesting that this compound 217 offers a biologically feasible treatment for SARS-CoV-2. 218 At the cellular level, CD4 ＋ T cells were rapidly activated to produce inflammatory cytokines 219 after SARS-CoV-2 infection, which further induced CD14 ＋ CD16 ＋ monocyte activation 220 with high levels of expression of interleukin 6 (IL-6). Thus, reduced IL-6 would potentially analyses to demonstrate that procyanidin can inhibit SARS-CoV-2 entry and replication (40). 232 In this study, we confirmed that procyanidin inhibits SARS-CoV-2 infection in the entry step. pcDNA3.1-SARS-CoV-2 S (ct19) by using a fast mutagenesis system (Transgene Biotech), 258 and mutations were confirmed by sequencing (Sangon, Shanghai). We used the same method 259 to generate the SARS-CoV-2 S variants pv. 260 Equal volumes of SARS-CoV-2 S pv (ct19) and SARS-CoV-2 S pv (wt) were treated with 262 DNase and RNase. RNA from the viruses was extracted using Trizol (TaKaRa) and reverse 263 transcribed using the PrimeScript™ RT reagent Kit (TaKaRa). Viral particles were quantified 264 via RT-qPCR using a specific primer pair to detect VSVΔG-Rluc (primers 265 5ʹ-GTAACGGACGAATGTCTCATAA-3ʹ and 5ʹ-TTTGACTCTCGCCTGATTGTAC -3ʹ). 266 Equal volumes of virus particles were precipitated with acetone and lysed using RIPA lysis 268 buffer. Lysates were treated with loading buffer, subjected to SDS-PAGE, and then 269 transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore). SARS-CoV-2 S 270 was detected using a rabbit anti-S2 subunit mouse monoclonal antibody (GeneTex, 271 GTX632604; 1:2000 dilution) . Horseraddish peroxidase-linked goat anti-mouse IgG antibody 272 (Proteintech, CHI, USA, 1:5000). 273 The appropriate cell density and the dose for SARS-CoV-2 S pv were selected by comparing 275 the signal-to-basal ratio, the coefficients of variation, and Z' values under different conditions, 276 as previously described. A library of 1,037 botanical compounds was purchased from 277 Weikeqi Biotech (Sichuan, China). The compounds were collected and stored in 10 mM stock 278 solutions in DMSO at -80 °C until use. The first round of HTS was carried out, and Caco-2 279 cells were seeded at a density of 2.4×10 4 cells per well in 96-well plates. After incubation 280 overnight, cells were treated in duplicate with the compounds (50 μM), and 1 h later, cells 281 were infected with SARS-CoV-2 S pv (ct19) with the MOI=5, and the supernatant was 282 removed 1 h.p.i. Camostat 100 μM and 0.5% DMSO were used as positive and negative 283 controls, respectively. After 24 h, luciferase activity was measured using the Rluc assay 284 system (Promega, Madison, WI, USA). The primary compounds were then secondarily 285 screened using VSV pv (MOI of 0.5) to rule out VSV genome replication inhibitors and Rluc 286 activity. 287 The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was 289 performed to evaluate the effect of the four hits on cell viability. Hits at the indicated 290 concentrations were added to pre-seeded Caco-2 cells in 96-well plates. Twenty-four hours 291 later, the cell viability was measured using the MTT kit. 292 Vero E6 cells were co-transfected with pcDNA3.1-SARS-CoV-2S (ct19) (0.25 μg) and 294 pEGFP-N1 (0.25 μg) by using lipo2000 in 24-well plates. After transfection for 4 h, the 295 medium was replaced with 2% DMEM containing different concentrations of the hits. After 296 24 h, syncytium formation was visualized using an M-shot image system (Micro-shot 297 Caco-2 cells were seeded at a density of 2.4×10 4 cells per well in 96-well plates. After 300 overnight incubation, cell monolayers were treated in duplicate with the hits at a final 301 concentration of 1 h and infected with SARS-CoV-2 at an MOI of 0.5. After an additional 24 302 h of incubation, the infection was stopped by rinsing each well, and the cells were fixed with 303 4% paraformaldehyde. Cells were permeabilized using PBS with 0.2% Triton X-100 for 15 304 min and blocked with 5% FBS (Gibco), followed by treatment with the primary antibody 305 anti-SARS-CoV-2 NP (GeneTex GTX635678, USA) at a 1:500 dilution overnight at 4°C. 306 After six rinses with PBS, the cells were stained with DyLight 488-labeled antibody against 307 rabbit IgG (KPL, Gaithersburg, MD, USA). Nuclei were stained with 308 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich, St. Louis, MO, USA). Nine fields per 309 well were imaged, and the percentages of infected and DAPI-positive cells were calculated 310 using Harmony 3.5 software. 311 Caco-2 cells were seeded at a density of 2.4×10 4 cells per well in 96-well plates. After Characteristics of SARS-CoV-2 and COVID-19 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by 342 a Clinically Proven Protease Inhibitor Computational Inference of Selection 344 Underlying the Evolution of the Novel Coronavirus Syndrome Coronavirus 2 Severe acute respiratory syndrome 348 coronavirus (SARS-CoV) infection inhibition using spike protein heptad 349 repeat-derived peptides Inhibition of SARS-CoV-2 (previously 352 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting 353 its spike protein that harbors a high capacity to mediate membrane fusion Establishment and 357 validation of a pseudovirus neutralization assay for SARS-CoV-2 360 The variant gambit: COVID-19's next move Emergence of a new SARS-CoV-2 variant in 362 the UK Initial Insights Into the Genetic Epidemiology of 368 SARS-CoV-2 Isolates From Kerala Suggest Local Spread From Limited 369 Introductions Spike mutation D614G alters SARS-CoV-2 fitness SARS-CoV-2 378 D614G variant exhibits efficient replication ex vivo and transmission in vivo SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity 385 of the COVID-19 Virus SARS-CoV-2 501Y.V2 variants lack 389 higher infectivity but do have immune escape Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera 392 and monoclonal antibodies SARS-CoV-2 396 variants B.1.351 and P.1 escape from neutralizing antibodies Plant products as antimicrobial agents A historical overview of natural products in 401 drug discovery Pseudotyped vesicular stomatitis virus for 403 analysis of virus entry mediated by SARS coronavirus spike proteins Measuring SARS-CoV-2 neutralizing antibody 409 activity using pseudotyped and chimeric viruses Development of cell-based 411 pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing 412 antibodies against SARS-CoV-2 Neutralizing Antibody and Soluble ACE2 417 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of 418 SARS-CoV-2 Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced 423 syncytia Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other 426 coronaviruses by depleting membrane cholesterol Cholesterol 25-hydroxylase suppresses 431 SARS-CoV-2 replication by blocking membrane fusion Structure of MERS-CoV spike 435 receptor-binding domain complexed with human receptor DPP4 Molecular basis of binding between novel human 439 coronavirus MERS-CoV and its receptor CD26 Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase 442 from severe acute respiratory syndrome coronavirus 2 with high potency Mechanism of SARS-CoV-2 polymerase 446 stalling by remdesivir A three-dimensional model to analyze drug-drug 448 interactions Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and 451 zidovudine Preclinical 456 profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor Natural products and chronic 459 hepatitis C virus In vivo effect of Schisandrin B on 461 cytochrome P450 enzyme activity Inhibitory effects of schisandrin A and 464 schisandrin B on CYP3A activity Alzheimer's Rats Updated Approaches against 469 SARS-CoV-2 471 Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+monocytes 472 in severe pulmonary syndrome patients of a new coronavirus Suppression of P2X7/NF-κB pathways by 475 Schisandrin B contributes to attenuation of lipopolysaccharide-induced inflammatory 476 responses in acute lung injury Light quality affects 478 flavonoid biosynthesis in young berries of Cabernet Sauvignon grape The potential role of 481 procyanidin as a therapeutic agent against SARS-CoV-2: a text mining, molecular 482 docking and molecular dynamics simulation approach Screening of 485 Botanical Drugs against Lassa Virus Entry Screening and Identification of Lassa Virus Entry Inhibitors from an 488 FDA-Approved Drug Library